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Dementia affects about 8% of people age 65 years and older. 
Identification of dementia is particularly difficult in its early phases 
when family members and physicians often incorrectly attribute 
the patient’s symptoms to normal aging. The most frequently 
occurring ailments that are connected with neurodegeneration 
are: Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease, amyotrophic lateral sclerosis, and multiple sclerosis. 
A variety of powerful techniques that have allowed visualization 
of organ structure and function with exact detail have been 
introduced in the last twenty-five years. One such neuroimag-
ing technique is positron emission tomography (PET), which 
measures in detail the functioning of distinct areas of the human 
brain and as a result plays a critical role in clinical and research 
applications. Radiotracer-based functional imaging provides 
a sensitive means of recognizing and characterizing the regional 
changes in brain metabolism and receptor binding associated 
with cognitive disorders.
The next functional imaging technique widely used in the diag-
nosis of cognitive disorders is single photon emission computed 
tomography (SPECT). 
New radiotracers are being developed and promise to expand 
further the list of indications for PET. Prospects for developing 
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Introduction
Despite the fact that extensive progress in neuroimaging 
techniques of the brain has been made, there is no specific pat-
tern of pathological changes in any type of dementia. This article 
is a brief review of the methods used in diagnosing the most 
frequent central nervous system diseases. We suppose that in 
the not-too-distant future it will be possible to assess not only the 
location, intensity, and aetiology of pathological dementive pro-
cesses but also techniques that will detect the earliest changes in 
brain structure. Functional neuroimaging, that is positron emis-
sion tomography (PET) and single photon emission computed 
tomography (SPECT), are essential techniques for detecting 
regional changes in metabolic activity of the brain and blood 
flow that are closely associated with mild cognitive impairment 
and dementia.
Parkinson’s disease
Parkinson’s disease (PD) is a degenerative and progressive 
disorder of the central nervous system. It has an estimated oc-
currence of up to 329/100,000 [1]. It belongs to a group of move-
ment disorders. It is characterized by motor (due to progressive 
degeneration of substantia nigra and other brain structures, which 
is connected with loss of dopamine- producing neurons) and 
non-motor symptoms [2]. The most characteristic motor symp-
toms are: tremor (resting), muscle rigidity, postural instability with 
problems with coordination, slowness of movements, bradykinesia 
(difficulty in initiating and stopping), and loss of physical movement 
(akinesia). The non-motor symptoms are specific for advanced 
stages of the disease and may include high-level cognitive dys-
function, psychiatric and emotional changes, depression, difficulty 
in swallowing and speaking, sensory symptoms, and constipation 
and/or urinary problems. The pathogenesis of Parkinson’s disease 
has still not been explained. Researchers focus on genetic and 
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environmental factors contributing to this chronic and progressive 
ailment [3].
An accurate diagnosis of Parkinson’s disease is crucial 
for the counselling and management of patients. Furthermore, 
proper diagnosis is also vital for conducting pharmacological 
and epidemiological studies. Frequently, recognition is based on 
clinical evaluation of symptoms over time and observations of the 
responses to applied therapies. Recently conducted research 
has shown that a high rate of misdiagnosis appeared when the 
diagnosis was founded only on clinical diagnostic criteria. Ano-
ther method which allows the detection of Parkinson’s disease 
is neuroimaging. Functional imaging techniques give a promis-
ing opportunity to find out the pathophysiology, progression, and 
complications of PD [5]. Various techniques have been used to 
visualize the extent of neuronal loss, and it can be measured in vivo 
using nuclear medicine tracers that bind selectively to dopamine 
neurons [2, 6–10].
Neuroimaging
Cranial computed tomography (cranial CT) and magnetic reso-
nance imaging (MRI) brain scans are usually applied. Structural 
imaging with cranial CT may be applied in PD without complica-
tions, which means abnormal brain changes in mild-to-moderate 
phases of PD. MRI presents a fundamentally greater role in 
diagnosis of central nervous system degenerative illnesses. MRI 
is superior to CT for visualisation of many cerebral abnormalities, 
particularly in the search for periventricular white matter abnor-
malities, which are frequently related to dementia. MRI has been 
applied in differentiation of Parkinson’s disease and atypical 
Parkinsonism [6, 11].
The application of imaging technologies such a positron emis-
sion tomography (PET) and single photon emission tomography 
(SPECT) radioligands is beneficial in detecting and characterising 
potential pathophysiological brain changes. It has been proven that 
these methods are of great importance in detecting early stages of 
cognitive impairment. Both of them contribute to the access of 
a topographic picture of brain function and detect impairment in 
cognitive domains [12]. 
Positron emission tomography (PET) presents the highest 
sensitivity. This method is able to detect femtomolar levels of 
positron-emitting radioisotopes at a spatial resolution of 3–5 mm 
and corrects for scatter. Positron emission tomography (PET) al-
lows the examination in vivo  of changes in regional cerebral blood 
flow glucose, oxygen, dopa metabolism, and brain receptor bind-
ing. Single photon emission tomography (SPECT) in comparison 
with positron emission tomography (PET) has lower sensitivity 
and is unable to correct for scatter. However, it is a more widely 
available method [11]. 
Imaging is divided into two groups: detecting changes in 
brain structure (structural imaging), and examining regional 
changes in brain metabolism and receptor binding asso-
ciated with disorder. Functional neuroimaging of nigrostriatal 
dopaminergic pathways is an important method for the evalu-
ation the dopaminergic terminals in the striatum. The func-
tion of dopamine terminals may be estimated in vivo in three 
pathways: the activity of terminal dopa decarboxylase (DDC), 
the availability of presynaptic dopamine transporters (DAT), 
and vesicle monoamine transporter density in dopamine ter-
minals (VMAT2). The radioligands are applied with both PET 
and SPECT [2, 11, 13, 14]. 
DOPA Decarboxylase (DDC)
DDC catalyses decarboxylation of L-DOPA to neurotransmitter 
dopamine.
The activity of DDC can be measured with 6-[18F]-L-dopa 
PET and it can be used as a means of  measurement of neuronal 
loss. Scanning using this tracer is still considered to be the gold 
standard method for monitoring the course of PD. The in vivo ac-
tion of 18F- DOPA depends on the conversion to 18F- dopamine by 
amino acid decarboxylase. Subsequently, 18F- dopamine is taken 
up and trapped in synaptic vesicles. 18F- DOPA is a marker of the 
accumulation and metabolism of levodopa. Uptake of this tracer 
relates to nigrostriatal cell loss and striatal concentrations of 
dopamine [7–11, 13–17]. 
Presynaptic dopamine active transporter (DAT)
DAT is an integral membrane protein that clears dopamine 
after its release in the synaptic cleft, thus terminating the signal 
of the neurotransmitter.
Radiotracers for measuring binding dopamine transporter are 
available for both PET and SPECT. Principally they are cocaine and 
tropane-based derivatives. 
PET tracers include: 11C-cocaine, 11C-CFT (carbometh-
oxy-3beta-[4-fluorophenyl]tropane), 18F-CFT, 11C-RTI-32 (methyl 
[1R-2-exo-3-exo]-8-methyl-3-[4-methylphenyl]-8-azabicyclo[3.2.1]
octane-2-carboxylate), 11C-nomifensine, and 11C-phenylethyl-
amine. These radiotracers bind to dopamine and noradrenaline 
reuptake sites. 
There SPECT tracers are: 123I-beta-CIT (carbomethoxy-3-
-[4-iodophenyl]tropane), 123I-FP-CIT (ioflupane), 123I-altropane, 
and 99mTc-TRODAT-1. The first gives the highest striatal:cerebellar 
uptake ratio of these SPECT tracers, but it binds non-selectively 
to dopamine, noradrenaline, and serotonin transporters. The 
main disadvantage of 123I-beta-CIT is the fact that scanning 
has to be deferred until the day after intravenous injection 
because it reaches equilibrium after 24 hours. Thus, SPECT 
tracers such as 123I-FP-CIT and 123I-altropane, despite their 
lower and time-dependent striatal:cerebellar uptake ratios, 
have become generally accepted and used. In comparison with 
123I-beta-CIT, these radiotracers enable a scan to be performed 
within 2–3 hours after injection [11, 18, 19]. 99mTc-TRODAT-1 
gives a lower 2:1 striatal:cerebellar uptake ratio than the 123I-
based tracers and is less well extracted by the brain; however, 
it possesses the virtue that it is potentially available in kit form 
[11]. The first binds non-selectively to dopamine, noradrenaline, 
and serotonin transporters [18, 19]. 
Using the D2–dopamine receptor binding tracers 
11C-raclo-
pride-PET and 123I-iodobenzamide (IBZM)-SPECT for the assess-
ment of D2 receptor density gives good results to evaluate PD 
patients [2, 6–11, 13, 15, 20].
Vesicular monoamine transporter (VMAT2)
VMAT2 is an integral membrane protein transporting 
monoamines — particularly neurotransmitters like dopamine, 
histamine, serotonin, and noradrenalin—into synaptic vesicles. 
It can be examined with 11C-dihydrotetrabenazine-PET [11, 20].
25www.nmr.viamedica.pl
Paweł Szymański et al. Neuroimaging diagnosis in neurodegenerative diseases
Review
In Parkinson’s disease there is observed not only a loss of 
dopamine, but also a reduction in serotonin concentration was ob-
served. Serotonin HT1A receptor binding in the midbrain may be 
measured with 11C-WAY100635-PET. This method permits the 
measurement of the functional integrity of serotoninergic neu-
rons [7, 9, 16].
Glial activation
Microglia are a type of glial cells that form the natural active 
immune defence in the central nervous system, but are also 
related to maintaining homeostasis. The highest concentra-
tions of microglia in the brain are observed in the substantia 
nigra. Activated cells of microglia produce various inflamma-
tory compounds, such as prostaglandins, cytokines, reactive 
forms of oxygen, and nitrogen. Induced by these factors, oxi-
dative stress may lead to an increase in neurodegeneration in 
PD. The mitochondria of activated microglia express peripheral 
benzodiazepine (BDZ) sites, which may be selectively bound 
by isoquinoline 11C-PK11195-PET — a new potential radiotracer 
for examining the inflammatory properties of neuroprotective 
agents in neurodegenerative disorders [2, 11]. The loss of 
substantia nigra neurons, characteristic of Parkinson’s disease, 
is associated with microglial activation. 11C-PK11195 enables the 
detection of increased signals in both the nigra and pallidum. 
The nigral 11C-PK11195 uptake reflects local degeneration, 
whereas the pallidal signal may result from the excess glutamate 
release from subthalamic projections, which are a consequence 
of dopamine deficiency [11]. 
To quantify the effect of nigrostriatal neuron degeneration [18F]
fluorodeoxyglukose-PET (FDG/PET) can be used, a glucose ana-
logue currently used for positron emission tomography imaging, 
or ethyl cysteine dimer-SPECT (ECD/SPECT) by measurement of 
regional rates of glucose utilization [14, 22, 23].
Alzheimer’s disease
Alzheimer’s disease is the most commonly occurring ailment 
among dementia in the elderly. It is a progressive neurodegen-
erative disorder, incurable at the current state of medical knowl-
edge. It is characterized by a progressive pattern of cognitive 
and functional impairment, associated with the loss of neurons in 
certain parts of the brain. Symptoms of this dementia like mem-
ory loss, problems with abstract thinking, planning, flexibility, 
motor tasks, neuropsychiatric manifestations, or language are 
connected with the loss of neurons and synapses in the cer-
ebral cortex and certain subcortical regions. In these parts of 
the brain characteristic pathological structures are observed: 
amyloid plaques (insoluble deposits of beta-amyloid protein 
called senile plaques), neurofibrillary tangles, and others, which 
may be the cause of neuronal death [24–27]. Alzheimer’s dis-
ease is characterized by hierarchical progress that means that 
information about the stage of AD is correlated with density and 
spatial distribution of lesions. [28]
Neuroimaging
Advances in medical technology allow not only improved di-
agnostic accuracy, but also accelerated treatment discovery. New 
neuroimaging methods currently being used can measure specific 
neurotransmitter systems, amyloid plaque, and tau tangle concen-
trations. Furthermore, neuronal integrity and connections between 
neurons might be evaluated by these techniques.
Structural neuroimaging with computerized tomography (CT) 
and volumetric magnetic resonance imaging (volumetric MRI) may 
reveal nondiagnostic cerebral atrophy observed in AD. Magnetic 
resonance imaging provides a sensitive method to study brain 
morphology, white matter, and vascular pathology. The improved 
resolution and higher soft tissue contrast offer greater potential 
for early diagnosis. Using MRI allows the measurement of the 
hippocampus and cortex-structures in the temporal lobe which 
are essential for normal memory function. MRI may also play 
a role in differentiating between Alzheimer’s disease and other 
dementias [18, 19, 29–34]. 
Magnetic resonance spectroscopy (MRS)
Magnetic resonance spectroscopy (MRS) is a source of in-
formation about concentrations of tissue substrate or metabolite. 
This technique uses the neuronal marker N-acetylaspartate to 
diagnose AD and MCI (mild cognitive impairment) and to monitor 
the metabolite changes to differentiate between patients with MCI 
and those with AD.
Proton magnetic resonance spectroscopy studies of occipital 
grey matter (measurement of levels of N-acetylaspartate and 
myo-inositol) may also be helpful in diagnosis of AD.
PET/SPECT
Neuroimaging techniques in AD have been used for the 
measurement of regional cerebral blood flow or regional glucose 
and oxygen metabolism [35]. Neuropathology studies show 
that patients with AD typically have lesions of the hippocampus, 
temporal and parietal neocortex, and entorhinal cortex [33, 36, 
37]. Functional brain imaging using SPECT to evaluate cerebral 
perfusion is a laboratory investigation that has been proposed 
as useful in the diagnosis of dementia [34, 38, 39]. PET and SPECT 
have the capacity to detect and quantify amyloid deposition in 
vivo when they are used in conjunction with trace amounts of 
radioligands [40].
Cerebral SPECT is based on brain uptake of lipid-soluble 
radionuclide- L,L-ethyl cysteinate dimer or hexamethylpropylene 
amine oxime containing technetium 99m as a tracer (99mTc-ECD, 
99mTc-HMPAO). These compounds are sensitive indicators of re-
gional cerebral blood flow and may help in the differentiation and 
evaluation of the severity of dementia. 99mTc-HMPAO is taken up 
in the brain within 2–5 minutes of intravenous injection and distrib-
utes according to blood flow. It is widely known that brain blood 
flow is closely coupled with brain metabolism as determined by 
glucose and oxygen utilization. Thus, Tc-HMPAO SPECT scans are 
regarded as a good method of measurement of brain function. 
Another radiotracer which may be applied for the measurement of 
regional cerebral blood flow is 123I-IMP-SPECT (N-isopropyl-p-[123I]
iodoamphetamine) [25, 39, 41–44]. Clinical indications for SPECT 
are mainly patients with suspected dementia. The main disadvan-
tage of SPECT is the fact that, unlike PET, imaging is not performed 
in real time. Furthermore, resolution is poor (10–15 mm), and what 
is more, similarly to CT, there is the need for exposure to radiation.
PET offers a more sensitive measure for detecting neuronal 
abnormalities prior to neuronal death. According to a multicenter 
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study, PET identified AD patients with a sensitivity and specificity 
of 94% and 73%, respectively. It has been used to determine the 
metabolic uptake of fluorine 18 [18F]-labelled 2 fluorodeoxyglu-
cose (2-deoxy-2-[18F]- fluoro-D-glucose- FDG) and blood flow in 
patients with dementia [18, 25, 29, 31, 37, 45–47].
It is estimated that Calcium ions accumulate in the dam-
aged nerve cell bodies and degenerating axons via a passive 
flow which is the result of a shortage of adenosine triphosphate 
(ATP) following ischaemia. 57Co (SPECT) and 55Co (PET), which 
are analogues of Ca2+, reflect Ca2+ influx in ischaemically or 
neurotoxically damaged cerebral tissue. So that these tech-
niques may be used for estimating focal neurodegenerative 
changes, endangered brain tissue or dead neurons, reactive 
gliosis, and inflammatory lesions in various dementias including 
Alzheimer’s disease [48] .
Amyloid plaques and tau tangle binding compounds
Amyloid plaques are the most characteristic pathological 
change in the brain of AD, and their basic components are 
insoluble deposits of beta-amyloid protein, dystrophic neuritis, 
inflammatory factors, and cellular material inside and outside the 
neurons. Amyloid fragments are reliable AD biomarkers because 
they directly reflect pathophysiological processes in AD [49].
The tau tangles are pathological proteins, located mainly 
in neuronal axons, which are composed of paired helical 
filaments (PHF) derived from abnormally hyperphosphorylated 
microtubule-associated protein tau [24, 42, 50–52]. 
The degenerative process in AD probably starts 20–30 
years before the clinical symptoms of the disease occur. There 
is a great need for biochemical diagnostic markers (biomarkers) 
that could assist in the diagnosis of AD in the early stages of the 
disease. They may also provide objective and reliable measure-
ments of drug safety and disease-modifying treatment efficacy in 
clinical drug trials in AD. 
Diagnostic markers for AD are divided into two groups: state 
markers and stage markers. State markers reflect the intensity 
of the disease process. The total amount of tau protein is an 
example of a state marker. The concentration of tau protein in 
the cerebrospinal fluid (CSF) probably indicates the intensity 
of the neuronal damage and degeneration. Stage markers give 
a measure of how far the degenerative process has proceeded. 
An example of a stage marker is atrophy of the hippocampus, 
which is measured by CT or MRI. 
The CSF is in direct contact with the extracellular space of 
the brain, and hence biochemical changes in the brain affect the 
CSF. Because AD pathology is restricted to the brain, CSF is an 
obvious source of biomarkers for AD. Biochemical markers for 
AD should reflect the central pathogenetic processes (the neu-
ronal degeneration, the deposition of amyloid-X peptide (AX) in 
plaques, and the hyperphosphorylation of tau with subsequent 
formation of tangles). Possible biomarkers for these pathogenetic 
processes are the concentrations in the CSF of total tau protein, 
and phosphorylated tau protein [53–56].
During the last few years there has been exponential growth 
in the development of radiolabelled peptides for diagnosis and 
therapy. Peptides can be labelled with a variety of radionuclides in-
tended for specific applications, diagnostic or therapeutic, by using 
both conventional and novel chelating moieties [57].
The main component of amyloid plaques (insoluble 
forms of beta-amyloid) may also constitute a target for ra-
diotracers. At present there are studies evaluating the practi-
cal application of the beta-amyloid binding compounds: 
[18F]-BAY94-9172, trans-4-(N-methyl-amino)-4’-{2-[2-(2-[18F] 
fluoro-ethoxy)-ethoxy]-ethoxy}-stilbene, 18F-labeled IMPY 
[6-iodo-2-(4’-N,N-dimethyl-amino) phenylimidazo [1,2-a]pyri-
dine], 2-(2-[2-demethylaminothiazol-5-yl]ethenyl)-6-(2-[Fluoro]
ethoxy)benzoxazole (BF-227), [11C]labelled Pittsburgh compound 
B (2-[4’-(methylamino)phenyl]-6-hydrobenzothiazole, PIB), 
[125I] IBOX (2-(40-dimethylaminophenyl)-6-iodobenzoxazole) 
and 18F-DDNP (2-(1-(6-[(2-[18F](fluoroethyl) (methyl)amino]-
2-naphthyl)ethylidene)malononitrile) as radiopharmaceuticals for 
PET-imaging of b-amyloid plaques and tau tangles (18F-DDNP). 
[18F]-BAY94-9172, an amyloid-b ligand, has been used with PET 
to distinguish patients with AD from those with frontotemporal 
dementia and healthy controls. Extensive PET studies using 
[11C]PIB, a derivative of thioflavin-T amyloid dye that binds to 
b-amyloid plaques but not tangles, show significantly greater 
cortical retention in patients with AD compared to controls. 
18F-DDNP – PET scanning differentiates patients with AD from 
those with MCI and cognitively intact controls, and initial lon-
gitudinal studies show that 18F-DDNP binding values increase 
as cognitive symptoms progress [25, 27, 31, 34, 47, 52, 58–60]. 
Huntington’s disease
Huntington’s disease, also known as Huntington’s chorea, 
is an autosomal, dominantly inherited, neurodegenerative 
disorder [61]. HD is characterized by a triad of motor, cogni-
tive, and emotional abnormalities [62]. Its symptoms include 
dystonia (involuntary limb movement), incoordination, cogni-
tive decline, and behavioral disturbances. It is typical for the 
first symptoms to appear in middle age, when patients usu-
ally have offspring and therefore have already (with different 
probabilities) passed the genetic malfunction onto the next 
generation. 
The diagnosis of HD is not difficult in a patient with a known 
family history, typical choreiform movements and cognitive dys-
function. The diagnosis may be more difficult in patients with 
uncharacteristic presentations or a lack of family history [62, 63].
Computed tomography scans (CT) and magnetic resonance 
imaging (MRI) usually do not show any structural changes of the 
brain in the early course of the disease; however, atrophy of the 
caudate and frontal cortex can be seen with the help of CT and 
MRI in the later stages of HD [64, 65]. 
Functional imaging using techniques such as positron emis-
sion tomography (PET) and single photon emission computed 
tomography (SPECT) have proven to be important tools when 
determining cerebral blood flow (both its decrease and increase) 
and local brain metabolism.
PET uses positron emitting radionuclides which have short 
half-lives such as 11C (half-life — 20 min.), 15O (2 min.), and 17F 
(110 min.). Due to the fact that radionuclides used for this method 
emit pairs of positrons going in opposite directions, PET is more 
accurate than SPECT and can also be used as a quantita-
tive method [61]. Routine magnetic resonance imaging (MRI) 
and computed tomography (CT) can detect different cerebral 
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changes as a direct result of Huntington’s disease; however, 
they are unable to help diagnose the disorder in its early stages. 
PET can provide information allowing the diagnosis of Hunt-
ington’s disease from as early as 9 to 11 years before the first 
symptoms appear [66, 67].
SPECT uses radionuclides, the half-lives of which are longer, 
i.e. 99Tc (6 h) or 123I (13 h). Due to this fact there is no need for the 
presence of a cyclotron; if such radiopharmaceuticals are avail-
able, SPECT is also a cheaper method than PET and is therefore 
more widely used. 
Cerebral blood flow and glucose metabolism
Regional cerebral blood flow (rCBF) and brain glucose 
metabolism can be determined with the help of 18F-deoxyglu-
cose — FDG PET. Their levels reflect the activity of groups of 
neurons in certain areas of the brain. Patients with early HD 
have reduced striatal glucose metabolism — hypometabolism 
in caudate is responsible for bradykinesia and dementia, puta-
men hypometabolism connects with chorea and eye-movement 
abnormalities. Dystonia is caused by thalamic hypometabolism 
[61, 68, 69]. Additionally, a significant reduction of glucose 
metabolism in the striatum has been reported in relatives at 
risk of HD [67]. 
Dopamine receptors
One of the first structural changes in the brain due to the HD 
is the loss of medium spiny neurons from the striatum. These 
neurons express dopamine receptors, D1 and D2, on their sur-
face. With the help of radiolabelled dopamine antagonists, like 
[11C]Raclopride, it is possible to observe the binding potential 
(BP) of dopamine receptors and therefore assess the damage 
that the disease has already caused. Andrews et al. believe that 
this method surpasses local metabolism evaluation, providing 
a more direct measure of disease progression [61].
Opioid receptors
Opioid receptors are a group of G-protein coupled recep-
tors with opioids as ligands. PET studies which involved the 
usage of [11C]diprenorphine as a tracer showed severe loss of 
opioid receptor binding in structures such as caudate, putamen, 
globus pallidus, midbrain, cingulate, and medial temporal cortex. 
However, these studies also revealed increased opioid receptor 
binding in the thalamus and prefrontal areas in patients with early 
HD. This may prove HD to be not only a basal ganglia disorder. It 
is worth mentioning that the loss of opioid receptors in the striatum 
was not as severe as the loss of dopamine receptors at similar 
stages of the disease [61].
Benzodiazepine receptors
Benzodiazepines (BDZ) bind to certain sites on the GABA 
receptor complex, causing increased GABA affinity towards its re-
ceptors. Use of [11C]flumazenil, a radiolabelled GABAA antagonist, 
showed reduced benzodiazepine binding in caudate, and normal 
benzodiazepine binding in putamen in HD patients with decreased 
glucose metabolism in both these neurological structures. The 
PET signal regarding normal putamen binding is most likely to 
be a result of increased in globus pallidus and decreased BDZ 
binding in putamen [61].
Microglial activation
The presence and the BP of active microglia can be de-
termined with the help of 11C-(R)-PK11195 as a tracer. The 
accumulation of active microglia can be seen in the striatum, 
globus pallidus, and frontal cortex. It corresponds very well with 
the neuronal loss [70].
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), known in the UK as mo-
tor neuron disease (MND), is, along with Alzheimer’s disease 
and Parkinson’s disease, one of the major neurodegenerative 
disorders, manifesting itself by a progressive deterioration of 
the corticospinal tract, brainstem, and anterior horn cells of the 
spinal cord [71, 72]. Motor neuron disease may manifest with 
pure upper motor neuron (UMN) degeneration as seen in primary 
lateral sclerosis (PLS), pure spinal lower motor neurons (LMNs) 
degeneration as seen in progressive muscular atrophy (PMA), 
pure bulbar LMN degeneration as seen in progressive bulbar 
palsy (PBP), or a combination of all the three as seen in the most 
frequently occurring form of ALS [73]. The symptoms are progres-
sive muscle atrophy, fasciculation (muscle twitching), spasticity, 
and hyporeflexia. ALS is a disease with poor prognosis and there 
is no radical cure or treatment; the clinical syndrome usually 
evolves to death within 3–5 years [74, 75]. 
Magnetic resonance imaging
Structural magnetic resonance imaging (MRI) of ALS pa-
tients may show signal changes in the corticospinal tract, but 
these have been reported in the minority of ALS patients. Corti-
cal atrophy emerges late in the disease and is hard to quantify. 
There have been CT studies reporting mild to moderate cortical 
atrophy in more than 60% of ALS individuals, but these have not 
been confirmed by other research centres. Functional magnetic 
resonance imaging (fMRI) is able to capture focal neuronal acti-
vation due to the increase in regional blood flow and increased 
regional oxygen extraction. However, the diagnostic value of 
fMRI — lack of sensitivity and specificity or no clear associa-
tions between MRI abnormalities in the corticospinal tract and 
disease stages — is, at present, questionable and should be 
addressed in future studies [73, 76].
Cerebral blood flow and glucose metabolism
SPECT imaging performed to evaluate brain perfusion with 
the help of 99mTc-ethyl cysteinate dimer (99mTc-ECD) shows a wide-
spread decrease in regional central blood flow (rCBF) in the frontal 
as well as the parietal cortex and the cortex around the bilateral 
central sulcus [77, 78]. PET studies using 2-18F-deoxy-D-glucose 
(FDG) have shown disturbed rCBF as well as disturbed glucose 
metabolism, especially in the sensorimotor cortex and the basal 
ganglia [76, 78].
Kalra et al., however, state that these techniques are unsuitable 
for patients due to their variability and sensitivity [78].
Glial activation
The ligand PK11195 (1-[2-chlorophenyl]-N-methyl-N-[1-me-
thyl-propyl]-3-isoquinolone carboxamide) specifically binds to 
the peripheral benzodiazepine binding site or the PBBS. PBBS 
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are expressed on the mitochondria of the microglia. Their in-
creased population is observed in different neurodegenerative 
disorders, including ALS. Radiolabelled PET ligand [11C](R)-
PK11195 is used to measure microglial activation. As a result 
of PET imaging a significant increase in ligand binding can be 
observed in the region of the motor cortex, pons, frontal lobe, 
and thalamus [79]. Unfortunately, this PET examination pro-
vides data of a more widespread microglial activation compared 
to imaging, with the help of PK11195, other neurodegenerative 
disorders. 
Postsynaptic dopamine D2 receptors
Another method used to help diagnose ALS would be the 
measurement of postsynaptic dopamine D2 receptor binding 
abilities. SPECT studies using 123I-benzamide (123I-IBZM), a specifi-
cally binding substance with D2 receptors, showed a significant 
decrease of postsynaptic striatal D2 receptor binding when com-
pared to results for control subjects [76, 80].
Benzodiazepine receptors
Similar to studies regarding Huntington’s disease, several 
positron emission tomography (PET) studies have shown sig-
nificantly decreased 11C-flumazenil (a radiolabelled antagonist of 
benzodiazepine receptor) binding in the primary sensory, premotor, 
prefrontal, thalamic, and parietal regions [72, 81].
Amyotrophic lateral sclerosis (ALS) with cognitive 
impairment
Although the classical neuropathological description of ALS 
focuses on the degeneration of selective motor neuron path-
ways, therefore regarding ALS as a motor neuron disease, more 
than one-third of described cases involve cognitive impairment. 
Amyotrophic lateral sclerosis with cognitive impairment (ALSci) 
also includes slight frontal and temporal lobe dysfunctions, which 
are responsible for difficulties in speaking, word finding, abstract, 
thinking, etc. 
Cerebral blood flow and glucose metabolism
The recognition of ALSci can be carried out with the help 
of both static and dynamic neuroimaging. The latter include 
techniques such as PET and SPECT. Both 123I-N-isopropyl-p-io-
doamphetamine (123I-IMP) and 99mTc-hexamethyl propylene 
amine oxime ([99mTc] –D,L- HMPAO) proved to be sensitive 
markers when determining frontotemporal dysfunction in SPECT 
studies. Both radiopharmaceuticals will show reduced frontal 
and temporal cortex blood flow, whereas FDG-PET studies are 
used to observe decreased glucose metabolism in frontal and 
temporal lobes [82]. 
Multiple sclerosis
Multiple sclerosis (MS) is a chronic neurological disorder 
characterised by demyelination of neurons in the central ner-
vous system, which results in the formation of scars better known 
as plaques or lesions [83]. Although the cause of MS is unknown, 
there is evidence suggesting an autoimmune mechanism which, 
some sources say, may be trigged by a viral infection. The condi-
tion is progressive yet very unpredictable and varies significantly 
between cases. MS may take several forms, with new symp-
toms occurring during attacks (relapsing form) or accumulating 
over time (progressive form). The usual symptoms are depression, 
fatigue, anxiety, personality change, tremor, unilateral loss of vi-
sion, pain, bladder problems, constipation, impaired hearing, etc. 
Around 50% of cases involve cognitive impairment.
MS causes inflammation, demyelination, and as a result 
degeneration. The blood-brain barrier loses its integrity and 
allows lymphocytes to migrate to CNS. The lymphocytes recog-
nise myelin as foreign body and so the inflammation process, 
targeted at the myelin sheath, begins. Lesions appearing in the 
course of MS are dynamic and they progress in time, as can be 
seen on MRI scans regarding different stages of the disease. 
Brain atrophy widely occurs and affects all brain structures, 
not only the white matter but the grey matter as well. However, 
brain atrophy may not be visible on MRI scans in the early 
stages of MS. This is simply due to the fact that all inflamed 
tissue tends to swell up; therefore, even though the patient 
has suffered neuronal loss there may not be any abnormali-
ties on the MRI scans [84].
Cerebral blood flow and glucose metabolism
PET imaging using 18FDG as an agent shows decreased re-
gional and global cerebral blood flow as well as decreased cerebral 
metabolic rate of glucose (CMRglc). Observed hypometabolism 
is widespread, affecting the cortical and deep central grey matter, 
supratentorial white matter, and infratentorial structures. However, 
the biggest decreases appear in the superior mesial frontal cortex, 
superior dorsolateral frontal cortex, mesial occipital cortex, lateral 
occipital cortex, deep inferior parietal white matter, and pons [85, 
86]. PET imaging provides more important information regarding 
pathological processes than MRI.
Acute or chronic?
Differentiation between the acute and chronic phases of 
multiple sclerosis may prove problematic. However, performing 
SPECT with the help of Tc-99m-MIBI as a radiopharmaceutical 
shows multiple accumulation points in patients with the acute form 
whereas in patients with chronic MS no focal points are visible [87].
Glial activation
 Very similar to the neuroimaging techniques assessing 
microglial activation in ALS, [11C](R)-PK11195 is used to deter-
mine the binding potential of peripheral benzodiazepine binding 
sites (PBBS), and therefore the amount and location of microglia. 
Microglial activation corresponds to lesion locations and is espe-
cially high at the lesion’s peripheral regions (active inflammatory 
process) [84, 85].
Spinal muscle atrophy
Spinal muscle atrophy (SMA) is a fatal, hereditary autosomal 
recessive disease which affects neuronal cells in the anterior 
horns of the spinal cord. It manifests clinically with symmetrical
limb and trunk weakness affecting the proximal more than the 
distal trunk muscles and the lower more than the upper limbs [88, 89]. 
The diagnosis of SMA is primarily based on the clinical fea-
tures and can also be supported by a positive family history.
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SPECT imaging with the help of 123I-N-isopropyl-p-iodoam-
phetamine (123I-IMP ) reveals areas of hypoperfusion such 
as the cerebral cortex, vermis, putamen, and frontal lobe [90]. 
This method, although not commonly used in SMA diagnosis, 
has proved sensitive in detecting CNS lesions.
Conclusions
To summarize, imaging using radiopharmaceuticals has been 
widely used for the investigation of dementing impairments during 
recent years. Molecular imaging offers a unique insight into the 
cholinergic, dopaminergic, and serotonergic systems that are 
inseparable elements of pathological processes that are observed 
in cognitive disorders. Moreover, these techniques allow the in-
vestigation of another structures related to dementing diseases: 
benzodiazepine receptors, opioid receptors, and glutamatergic 
receptors. The molecular imaging not only permits the obser-
vation of the pathophysiology and mechanisms of dementing 
disorders but also helps to evaluate the effects of treatment with 
drugs and may promote future drug developments. The continuing 
study of new techniques for imaging the central nervous system 
is expected to produce significant advances in our understanding 
of the changes in brain structure and function that are associated 
with neurodegenerative disorders. 
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